Wolfe Research reiterates Peerperform on Madrigal stock By Investing.com - ca.investing.com

Madrigal reported Q4 2025 EPS of -$2.57 vs. consensus -$0.60 (large miss) while revenue beat at $321.1M vs. $310.82M expected. The stock has climbed to $530.61 (+13.3% weekly, +62% Y/Y) amid M&A speculation; Wolfe Research reiterates Peerperform citing strategic M&A fit and underappreciated long-term Rezdiffra revenue potential. Truist and H.C. Wainwright reiterated Buy ratings with $640 and $620 price targets respectively; company reported 432% revenue growth L12M, 94% gross margins, and nearly $1B in Rezdiffra net sales since launch.

Analysis

Madrigal sits at the intersection of M&A optionality and chronic-disease commercial optionality; the market is effectively pricing a binary takeout or rapid label expansion, not the gradual, multi-year revenue ramp that combination therapy adoption implies. That creates a wedge where a strategic buyer can pay a high contingent premium (CVR-heavy) to capture upside while limiting near-term cash — a structure that should increase M&A probability within 6-18 months but compress near-term arbitrage returns for straight equity holders.

Second-order beneficiaries include CMOs and specialty pharmacy logistics providers that would need to scale manufacturing and distribution if diagnosis rates accelerate; conversely, mid-stage NASH rivals without clear combination strategies or payor dossiers are vulnerable to talent and partnership raids. Payer implementation is the single largest choke point: if payors demand fibrosis-stage restrictions or outcome-based contracting, realized peak sales could fall materially vs. headline addressable market assumptions.

Key tail risks are reimbursement stalls and safety/regulatory signals from broader NASH combination trials that could reset expectations in weeks to quarters, and a strategic buyer choosing a low-upfront/CVR-heavy structure that leaves public shareholders long optionality with limited near-term liquidity. The most likely positive catalyst is a takeover conversation that surfaces via mandated filings or controlled process leaks; absence of such a process within 12 months should materially lower the probability-adjusted upside.

From a portfolio-construction view, the optimal stance is to express upside while controlling binary risk: sell time into noise, hedge sector beta, and size for outcomes rather than headline momentum. Volatility will remain elevated around earnings, guideline updates, and any M&A chatter — use that to scale exposures rather than committing full size at current sentiment levels.

Key Decisions for Investors

• Directional equity with risk control: Buy MDGL on a staged basis into weakness (scale in 30% at 0%-10% pullback, additional 40% at 10%-20% pullback) with a 30% trailing stop; target 50%-100% upside over 12-24 months under a contested M&A or favorable label expansion scenario, downside capped to sizing discipline.
• Volatility-defined call-spread (asymmetric payoff): Buy 12–18 month MDGL 30–40-delta calls and sell shorter-dated calls to finance ~50% of premium (calendar-call spread). This keeps upside exposure to an M&A or approval event while collecting theta against near-term EPS/noise risk; expect 2–4x return if a deal or clear commercial acceleration emerges, max loss = net premium.
• Pair hedge to isolate idiosyncratic upside: Long MDGL equity + short equal-dollar XBI (or IBB) to neutralize sector beta for 6–18 months. If MDGL re-rates on deal talks or label expansion, expect asymmetric outperformance; if broad biotech risk-off hits, hedge reduces portfolio drawdown.
• Event arbitrage sizing rule: If a buyer files a 13D/TO or confirmed process starts, convert option exposure to outright long and size to 3–5% position; otherwise keep exposure <1.5% until proof of process, because probable CVR-heavy deals compress near-term cash realizations.